PH19902A - Long-acting formulation of cefaclor - Google Patents

Long-acting formulation of cefaclor

Info

Publication number
PH19902A
PH19902A PH30800A PH30800A PH19902A PH 19902 A PH19902 A PH 19902A PH 30800 A PH30800 A PH 30800A PH 30800 A PH30800 A PH 30800A PH 19902 A PH19902 A PH 19902A
Authority
PH
Philippines
Prior art keywords
cefaclor
long
acting formulation
release component
formulations
Prior art date
Application number
PH30800A
Other languages
English (en)
Inventor
Teruo Sakamoto
Sadao Kawai
Kinzaburo Noda
Toyohiko Takeda
Hiroshi Kato
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of PH19902A publication Critical patent/PH19902A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PH30800A 1983-06-15 1984-06-11 Long-acting formulation of cefaclor PH19902A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58108289A JPS601128A (ja) 1983-06-15 1983-06-15 作用持続型セフアクロル製剤

Publications (1)

Publication Number Publication Date
PH19902A true PH19902A (en) 1986-08-13

Family

ID=14480890

Family Applications (1)

Application Number Title Priority Date Filing Date
PH30800A PH19902A (en) 1983-06-15 1984-06-11 Long-acting formulation of cefaclor

Country Status (23)

Country Link
US (1) US4713247A (fr)
EP (1) EP0129382B1 (fr)
JP (1) JPS601128A (fr)
KR (1) KR910004573B1 (fr)
AT (1) ATE56869T1 (fr)
AU (1) AU568654B2 (fr)
BG (1) BG60261B2 (fr)
CA (1) CA1213218A (fr)
DD (1) DD216163A5 (fr)
DE (1) DE3483282D1 (fr)
DK (2) DK170922B1 (fr)
ES (1) ES8602407A1 (fr)
FI (1) FI84556C (fr)
GB (1) GB2141342B (fr)
GR (1) GR81598B (fr)
HU (1) HU193434B (fr)
IE (1) IE58278B1 (fr)
IL (1) IL72083A (fr)
NZ (1) NZ208345A (fr)
PH (1) PH19902A (fr)
PT (1) PT78699B (fr)
RO (1) RO88924A (fr)
ZA (1) ZA844357B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229132A (en) * 1985-02-22 1993-07-20 Grimberg Georges Serge Non-absorbable gastrointestinal medicament provided for treating the two levels of the digestive tract at the same time
JPS61210025A (ja) * 1985-03-14 1986-09-18 Teisan Seiyaku Kk 安定化された抗生物質複合顆粒製剤
AU591248B2 (en) * 1986-03-27 1989-11-30 Kinaform Technology, Inc. Sustained-release pharaceutical preparation
JPS62226926A (ja) * 1986-03-27 1987-10-05 Teisan Seiyaku Kk 持続性複合顆粒剤
JPH0714863B2 (ja) * 1986-06-02 1995-02-22 忠生 白石 時差溶解性の入浴剤
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
NZ223619A (en) * 1987-02-27 1990-10-26 Lilly Co Eli Sustained release tablet containing cefaclor, a hydrophilic polymer and an acrylic polymer
BE1002079A4 (fr) * 1988-07-01 1990-06-19 S M B Lab Composition pharmaceutique d'erythromycine a liberation prolongee, sa preparation et son utilisation.
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
CA2085342A1 (fr) * 1990-06-14 1991-12-15 Milton R. Kaplan Suspension aqueuse stable de medicament
GB9318641D0 (en) * 1993-09-08 1993-10-27 Edko Trading Representation Compositions
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
AU5107496A (en) * 1996-03-13 1997-10-01 Labtec Gesellschaft Fur Technologische Forschung Und Entwicklung Mbh Medicament preparation for angiotensin converting enzyme (ace)-inhibitors
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
ZA98728B (en) * 1998-01-29 1998-10-28 Ranbaxy Lab Ltd Modified release matrix formulations of cefactor and cephalexin
KR100296413B1 (ko) * 1998-04-01 2001-11-14 김선진 세파클러함유서방성정제
US20030170181A1 (en) * 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
EP1165054A4 (fr) * 1999-04-06 2005-02-09 Pharmaquest Ltd Forme posologique pharmaceutique permettant l'administration intermittente de methylphenidate
AU4441899A (en) * 1999-05-14 2000-12-05 Eli Lilly And Company Process for preparing pharmaceutical bulk material having uniform dissolution
US6596307B1 (en) 1999-06-15 2003-07-22 Eli Lilly And Company Process for preparing pharmaceutical bulk material having uniform dissolution
AU2001239841B2 (en) * 2000-02-24 2006-04-27 Shionogi, Inc. Antibiotic and antifungal compositions
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
CA2399856C (fr) * 2000-02-24 2009-01-27 Edward M. Rudnic Composition antibiotique dotee d'inhibiteurs
JP2003523378A (ja) * 2000-02-24 2003-08-05 アドバンシス ファーマシューティカル コーポレイション 治療剤製品、その使用及び製剤形態
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
JP2004520358A (ja) * 2001-01-18 2004-07-08 ナトコ ファーマ リミテッド 改良された治療効能を有するβ−ラクタム抗生物質を含む徐放性薬剤組成物
JP2005526059A (ja) * 2002-03-07 2005-09-02 アドバンシス ファーマスーティカル コーポレイション 抗生物質組成物
WO2003094899A1 (fr) * 2002-05-09 2003-11-20 Diffucap-Chemobras Química E Farmacéutica, Ltda. Nouveau procede pour la preparation de compositions a liberation programmee contenant (s) -1- [n-[1-(ethoxycarbonyl)-3-phenylpropyl]-l-alanyl]-l-proline, et produit ainsi obtenu
CA2533358C (fr) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Produit antibiotique, utilisation et formulation associees
WO2005009368A2 (fr) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Produit antibiotique, utilisation et formulation correspondantes
WO2005009365A2 (fr) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Produit antibiotique, son utilisation et sa formulation
US8062672B2 (en) * 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
AU2004270170B2 (en) * 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005027877A1 (fr) * 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotique, son utilisation et sa formulation
EP1667661A1 (fr) * 2003-09-30 2006-06-14 Lupin Limited Formulation de liberation etendue d'antibiotiques de type beta-lactame
CA2602268A1 (fr) * 2005-04-12 2006-10-19 Elan Pharma International Limited Compositions a liberation controlee comportant une celphalosporine pour le traitement d'une infection bacterienne
EP1890676A2 (fr) 2005-06-02 2008-02-27 Novozymes A/S Melanges de particules inactives et de particules actives
US20060287212A1 (en) * 2005-06-02 2006-12-21 Novozymes A/S Blends of inactive particles and active particles
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
SMT201700097T1 (it) 2009-05-19 2017-03-08 Celgene Corp Formulazioni di 4-ammino-2-(2,6-diossopiperidin-3-il)isoindolin-1,3-dione
CN110384701A (zh) * 2011-12-19 2019-10-29 萨利克斯药品有限公司 使用甲基纳曲酮口服组合物治疗和预防阿片类诱发型便秘的方法
CA2902911C (fr) 2014-10-31 2017-06-27 Purdue Pharma Methodes et compositions destinees au traitement du trouble de deficit d'attention
CN104688701A (zh) * 2015-03-20 2015-06-10 江苏亚邦强生药业有限公司 一种头孢克洛片剂及其制备方法
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN110408670A (zh) * 2019-08-19 2019-11-05 苏州盛达药业有限公司 一种酶催化合成头孢克洛的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US3906086A (en) * 1971-07-19 1975-09-16 Richard G Powers Timed-release aspirin
JPS52139713A (en) * 1976-05-13 1977-11-21 Shionogi & Co Ltd Sustained release cefalexin preparations
US4250166A (en) * 1977-05-27 1981-02-10 Shionogi & Co., Ltd. Long acting preparation of cefalexin for effective treatments of bacterial infection sensitive to cefalexin
GR74995B (fr) * 1980-08-27 1984-07-12 Ciba Geigy Ag
JPS5826816A (ja) * 1981-08-11 1983-02-17 Teisan Seiyaku Kk 球形顆粒からなる持続性複合顆粒剤

Also Published As

Publication number Publication date
PT78699A (pt) 1985-01-01
KR910004573B1 (ko) 1991-07-06
JPS601128A (ja) 1985-01-07
IL72083A (en) 1987-10-30
GB2141342B (en) 1986-11-12
IE841444L (en) 1984-12-15
RO88924A (fr) 1986-04-30
GR81598B (fr) 1984-12-11
DD216163A5 (de) 1984-12-05
EP0129382A3 (en) 1986-07-09
KR850000242A (ko) 1985-02-26
PT78699B (en) 1986-07-15
JPS6232166B2 (fr) 1987-07-13
DE3483282D1 (de) 1990-10-31
ES533901A0 (es) 1985-12-01
DK291884D0 (da) 1984-06-14
NZ208345A (en) 1986-12-05
FI842406L (fi) 1984-12-16
BG60261B1 (bg) 1994-03-31
AU2941884A (en) 1984-12-20
DK291884A (da) 1984-12-16
AU568654B2 (en) 1988-01-07
FI84556B (fi) 1991-09-13
GB2141342A (en) 1984-12-19
CA1213218A (fr) 1986-10-28
ZA844357B (en) 1985-06-26
GB8414633D0 (en) 1984-07-11
FI842406A0 (fi) 1984-06-13
FI84556C (fi) 1991-12-27
ATE56869T1 (de) 1990-10-15
IL72083A0 (en) 1984-10-31
BG60261B2 (en) 1994-03-31
EP0129382B1 (fr) 1990-09-26
IE58278B1 (en) 1993-08-25
EP0129382A2 (fr) 1984-12-27
US4713247A (en) 1987-12-15
ES8602407A1 (es) 1985-12-01
HUT34692A (en) 1985-04-28
DK170922B1 (da) 1996-03-18
HU193434B (en) 1987-10-28

Similar Documents

Publication Publication Date Title
GB2141342B (en) Long-acting formulation of cefaclor
HUT41221A (en) Insecticide and acaricide compositions further process for preparing phenoxy-alkyl-amino-pyridine derivatives as active ingredients thereof
HUT47131A (en) Process for producing steroid-5alpha-reductase inhibitors and pharmaceutical compositions comprising them as active ingredient
HUT46654A (en) Process for producing substituted basic 2-amino-tetralin derivatives and pharmaceutical compositions comprising the same as active ingredient
HUT51222A (en) Process for producing 9-halogen-/z/-prostaglandin derivatives and pharmaceutical compositions comprising such active ingredient
NO308538B1 (no) Imidazo (4,5-c) kinolinaminer
HUT51269A (en) Process for producing benzimidazole derivatives and pharmaceutical compositions comprising same
HUT48247A (en) Process for producing aza-bicyclo-octyl-ether derivatives and pharmaceutical compositions containing them as active components
HUT64013A (en) Process for producing hiv-inhibiting phenylacetamide derivatives and pharmaceutical compositions comprising such compounds as active ingredient
HUT49367A (en) Process for producing aristeromycin/adenosine derivatives and pharmaceutical compositions comprising same as active ingredient
ES2002083A6 (es) Un metodo para preparar derivados de piroglutamida
HUT47210A (en) Insecticide compositions and process for producing benzoyl-urea derivatives as active components
HUT43848A (en) Process for producing pyridinyl-piperazine derivatives and pharmaceutical compositions containing them as active agents
HUT48642A (en) Process for producing amino-acid derivatives and pharmaceutical compositions containing them as active components
HUT47127A (en) Process for producing pyrimidine derivatives and pharmaceutical compositions comprising such active ingredient
HUT46013A (en) Process for producing mono- and diepoxides of 23-oxo- and 23-imino-derivatives of ll-f28249 compounds and pharmaceutical compositions containing them as active components ; and insecticide compositions
HUT47902A (en) Process for producing anilino-phenyl-thiourea-, -isothiourea- and -carbodiimid derivatives and insecticide compositions containing them as active components
HUT63168A (en) Process for producing tetracyclic antibiotics and pharmaceutical compositions comprising same as active ingredient
HUT48885A (en) Process for producing nukleotid-analogues and pharmaceutical compositions containing them as active components
HUT49590A (en) Process for producing benzimidazole derivatives and pharmaceutical compositions comprising same as active ingredient
PT75281A (en) Process for the preparation of biologically active hydrazonocephem derivatives and of pharmaceutical compositions containing the same
HUT49112A (en) Process for producing new 1-aryloxy-3-amino-2-propanols and pharmaceutical compositions comprising such active ingredient
HUT53108A (en) Process for producing penem derivatives and pharmaceutical compositions comprising such active ingredient
HU896610D0 (en) Herbicid composition comprising substituted-sulfonyl-urea as active ingredient and process for preparation thereof
EP0132772A3 (en) Fr-900216 substance obtainable by cultivating atcc 20577 for use as an active therapeutic substance and pharmaceutical antitumor composition comprising fr-900216 substance